WARNING LETTER
JJLBRO
MARCS-CMS 729873 —
June 17, 2026
Delivery Method:
VIA ELECTRONIC MAIL READ/DELIVERY RECEIPT REQUESTED
Product:
Drugs
Recipient:
JJLBRO
Romvy E-Ticaret Limited Sirketi
Oba Başaranlar Sk. No: 16
07400
/
Antalya
Turkey
eroxoninmed@gmail.com
Issuing Office:
Center for Drug Evaluation and Research (CDER)
United States
June 17, 2026
WARNING LETTER
Reference Number: 729873
To JJLBRO and Romvy E-Ticaret Limited Sirketi:
This warning letter advises you of significant violations observed during a U.S. Food and Drug Administration (FDA) review of your website. Promptly address the violations described herein without delay, including ensuring that appropriate resources are allocated to fully address the violations and prevent their recurrence. This is not intended to be an all-inclusive list of the violations that may exist in connection with your products or operations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations. Failure to adequately address violations may result in regulatory or legal action without further notice including, without limitation, seizure and injunction.
FDA Review
Violations were identified and documented during a review of your website https://jjlbro.com/ in May 2026. We also reviewed your Amazon storefront in May 2026.
1
Based on our review, “Men’s Foreskin Repair Gel,” “Size’Up Chrono Erect,” “Penile Health Cream,” “Men’s External Delayed Spray,” and “Men’s Penis XXL Care Cream” are unapproved new drugs under section 505(a) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. 355(a). As explained further below, introducing or delivering these products for introduction into interstate commerce violates sections 301(d) and 505(a) of the FD&C Act, 21 U.S.C. 331(d) and 355(a).
This review was conducted as part of FDA's public health responsibility to protect the public from unsafe, ineffective, and poor-quality drugs.
Violations of the Federal Food, Drug, and Cosmetic Act
The following are violations identified during our review. As a reminder, this is not an all-inclusive list of violations that may exist in connection with your products or operations.
Unapproved New Drug Violations
Based on a review of your website, “Men’s Foreskin Repair Gel,” “Size’Up Chrono Erect,” “Penile Health Cream,” “Men’s External Delayed Spray,” and “Men’s Penis XXL Care Cream” are drugs under section 201(g)(1) of the FD&C Act, 21 U.S.C. 321(g)(1), because they are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease, and/or intended to affect the structure or any function of the body. Examples from your product labeling, including on your website, that provide evidence of the intended use (as defined in 21 CFR 201.128) of these products as drugs include, but may not be limited to, the following:
Men’s Foreskin Repair Gel
On the webpage https://jjlbro.com/products/mens-extra-power-foreskin-repair-enhancement-gel?variant=41998671478878:
“DOUBLE LINE CARE, DIRECT HIT PHIMOSIS”
“ABSORPTION OF INTERNAL ADHESIONS”
“TO PROMOTE THE VITALITY OF PRIVATE CELLS FROM THE CONGENITAL PHIMOSIS”
Size’Up Chrono Erect
On the webpage https://jjlbro.com/products/mens-size-up-chrono-erect-enlargement-cream-extra-power-massage-gel-oil-for-huge-thickness-strength-and-prolonged-performance?variant=41998765916254:
“Proven Size Enhancement: Clinically . . . shown to help promote blood flow and stimulate cell growth, leading to visible results in size enhancement with consistent use.”
“Prolonged Performance: Men’s Size Up Chrono Erect Enlargement Cream supports prolonged performance by stimulating circulation and energy flow, improving stamina and endurance.”
Penile Health Cream
On the webpage https://jjlbro.com/products/male-performance-med3000-enhancement-gel?variant=41998765850718:
“BOOST MUSCLE STRENGTH”
“ENHANCES LIBIDO AND PLEASURE”
“INCREASE ENERGY AND STAMINA”
“IMPROVE MALE REPRODUCTIVE HEALTH”
“Naturally Boosts Energy, Libido, Fertility, Mood, and Hormonal Balance.”
“Enhances intimacy, Improves Blood Flow, and Elevates Performance.”
“Believed to Support Brain Health, Soothe Pain, and Reinforce Masculinity.”
Men’s External Delayed Spray
On the webpage https://jjlbro.com/products/mens-best-external-delay-enhancement-spray:
“Prolonged Performance: Allows for extended enjoyment and satisfaction”
“Quick-Acting Formula: Starts working within minutes for immediate results, so you’re always prepared.”
“PREMATURE EJACULATION MAKES MEN MISERABLE”
“MAY STIMULATE CAVERNOUS BODIES, REPRODUCTIVE GLANDS, NERVOUS SYSTEM IT MAKES IT PLAY A NORMAL FUNCTION, NOT ONLY TO HELP WITH OVERTIME, BUT ALSO TO HELP THE ERECTION FUNCTION”
Men’s Penis XXL Care Cream
On the webpage https://jjlbro.com/products/men-s-care-ultra-enlargement-cream-jjlbro-huge-xxl-extra-strength-growth-cream-for-mens-size-power-xxl-care?variant=41998751563870:
“SEXUAL EXCITEMENT”
“LAST LONGER”
“LARGER SIZE”
“HUGE”
“Proven Size Enhancement: Clinically . . . shown to help promote blood flow and stimulate cell growth, leading to visible results in size enhancement with consistent use”
“Prolonged Performance . . . by stimulating circulation and energy flow, improving stamina and endurance”
“Men’s Foreskin Repair Gel,” “Size’Up Chrono Erect,” “Penile Health Cream,” “Men’s External Delayed Spray,” and “Men’s Penis XXL Care Cream” are “new drugs” under section 201(p) of the FD&C Act, 21 U.S.C. 321(p), because they are not generally recognized as safe and effective (GRASE) for use under the conditions prescribed, recommended, or suggested in their labeling. With certain exceptions not applicable here, a new drug may not be introduced or delivered for introduction into interstate commerce without an approved application from FDA in effect, as described in section 505(a) of the FD&C Act, 21 U.S.C. 355(a). No approved applications pursuant to section 505 of the FD&C Act, 21 U.S.C. 355, are in effect for these products. Accordingly, these products are unapproved new drugs. The introduction or delivery for introduction into interstate commerce of these unapproved new drug products violates sections 301(d) and 505(a) of the FD&C Act, 21 U.S.C. 331(d) and 355(a).
Conclusion
As previously stated, you are responsible for investigating and determining the root causes of any violations and implementing corrective and preventative measures to ensure sustained compliance so that these violations and any others do not occur.
Send your written response to FDAAdvisory@fda.hhs.gov within fifteen (15) business days of receipt of this letter. Include the specific steps you have taken to correct any violations, an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. Identify your response with reference number “729873” in the subject line of the email.
If you have information that you believe demonstrates that your products are not in violation of the FD&C Act and FDA regulations, include that information for our consideration.
Please note FDA posts warning letters on www.fda.gov.
Sincerely,
/S/
Tina Smith, M.S.
Captain, U.S. Public Health Service
Director
Office of Unapproved Drugs and Labeling Compliance
Office of Compliance
Center for Drug Evaluation and Research
U.S. Food and Drug Administration
__________________________
1
https://www.amazon.com/s?i=merchant-items&me=A327E0NFTQVK94&marketplaceID=ATVPDKIKX0DER&qid=1778778461&xpid=ogniWslo1h6zF&ref=sr_pg_1
Content current as of:
06/23/2026
Regulated Product(s)
Drugs